
Director, Marketing - Thought Leader Engagement Strategy
Kura Oncology
118,382 marketing jobs

Kura Oncology

Faraday Future

Faraday Future

Faraday Future

AAA Club Alliance

University of Cincinnati

Zwilling JA Henckels LLC

HOKA

Microsoft

Atari
Guardian Real Estate Services LLC

delight.ai

delight.ai

delight.ai

medmix

Alion

Versa Networks

Versa Networks

Knix

Knix
San Diego, CA (On-site)
Posted 2 weeks ago
Own and drive the OL engagement strategy across speaker programs, advisory boards, KOL engagement, and cross-functional partnerships to deliver physician education and strategic insights that inform commercial decisions.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
Posted range
$234K/yr – $262K/yr
Taken straight from the job posting.